News Search Results
Feb 18, 2026, 12:00 ET Lifespan Vision Ventures Co-Leads Sift Biosciences' $3.7M Pre-Seed Financing
Directors. About Lifespan Vision Ventures Lifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven
More news about: LifeSpan Vision Ventures
Feb 18, 2026, 11:46 ET Hydrophobic Interaction Chromatography Market to Reach $952.9 Million, Globally, by 2033 at 7.5% CAGR: Allied Market Research
during the forecast period. This is attributed to growing demand for high-quality chromatography products, particularly in biopharmaceuticals and biotechnology industries. The increasing use of hydrophobic interaction chromatography for the purification of monoclonal antibodies, therapeutic proteins, and
More news about: Allied Market Research
Feb 18, 2026, 11:16 ET Astaxanthin Market to Reach $1.6 Billion, Globally, by 2033 at 8.1% CAGR: Allied Market Research
rising health awareness, and growing demand for nutraceuticals and cosmetics in countries such as China, Japan, and India. Increasing investments in biotechnology and expanding middle-class population with higher disposable income further support regional growth.For Purchase Related Queries/Enquiry
More news about: Allied Market Research
Feb 18, 2026, 11:01 ET Egg White Substitute Market to Reach US$ 2.3 Billion by 2033 as Vegan & Functional Food Trends Drive Growth As per Persistence Market Research
Market by Product Type (Liquid Egg Whites, Liquid Egg Yolks, Liquid Whole Eggs), Source (Cage-free, Conventional), Application (Food Industry, Biotechnology, Cosmetic Industry), and Regional Analysis for 2025 - 2032About Persistence Market Research:At Persistence Market Research,
More news about: Persistence Market Research Pvt. Ltd.
Feb 18, 2026, 09:05 ET NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term
More news about: NeuroSense
Feb 18, 2026, 09:00 ET GMP Labeling Partners with Loftware for Digital Label Solutions
integrate physical labels, label printers, and integrated software, addressing the evolving regulatory needs of medical device, pharmaceutical, and biotechnology industries.
More news about: GMP Labeling Inc.
Feb 18, 2026, 09:00 ET ICON plc Faces Investigation After Internal Probe Reveals Multi-Year Revenue Overstatement
world's largest contract research organizations, providing outsourced drug development and clinical trial management services to pharmaceutical and biotechnology companies. The CRO industry relies on long-term service contracts that typically span multiple years, making accurate revenue recognition a critical
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 09:00 ET Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility
research organizations (CROs) in the clinical-trial industry, providing Phase I through Phase IV drug development services to pharmaceutical and biotechnology companies worldwide. In the CRO sector, the book-to-bill ratio serves as the primary forward-looking indicator of business health. Because CRO revenues
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 08:54 ET Iaso Therapeutics to Showcase Novel mQβ Vaccine Platform at 2026 World Vaccine Congress
EAST LANSING, Mich., Feb. 18, 2026 /PRNewswire/ -- Iaso Therapeutics, Inc., a biotechnology company redefining infectious disease prevention with its novel synthetic vaccine platform, today announced that it will present at the 2026 World
More news about: Iaso Therapeutics, Inc.
Feb 18, 2026, 08:50 ET Draper Achieves Sustained Recirculation of Immune Cells in a Microphysiological System (MPS)
meet our customers' requirements. These efforts focus on four critical mission areas: Strategic Systems, Space Systems, Electronic Systems, and Biotechnology Systems. To extend our legacy into the future, the
More news about: Draper Laboratory
Feb 18, 2026, 08:35 ET Mecademic Secures Strategic Funding to Drive Global Expansion
next growth phase."Demand for Mecademic's micro-automation solutions is rising in sectors like electronics, optics, medical devices, and biotechnology. Its ultra-compact robotic arms allow manufacturers and labs to integrate high-speed, precise automation into confined spaces where traditional
More news about: Mecademic Industrial Robotics
Feb 18, 2026, 08:32 ET Jeonbuk National University Researchers Develop an Innovative Prussian-Blue Based Electrode for Effective and Efficient Cesium Removal
increasing system complexity and operational costs.A research team led by Professor Jum Suk Jang from the Department of Integrative Environmental Biotechnology, College of Environmental and Bioresource Sciences at Jeonbuk National University, South Korea, developed an innovative method for fabricating PB
More news about: Jeonbuk National University
Feb 18, 2026, 08:30 ET E-Biotech® Launches Patent-Pending AI Regulatory Intelligence Infrastructure for Pharmaceutical and GMP Compliance
Regulatory and GMP operations across pharmaceutical and biotechnology organizations remain fragmented across siloed software systems, static documentation tools, and manually intensive compliance workflows. While enterprise
More news about: E-BIOTECH Inc.
Feb 18, 2026, 08:24 ET Renowned Filmmaker and Creative Director Dr. Bob Gordon Joins Immorta Bio Strategic Advisory Board
MIAMI, Feb. 18, 2026 /PRNewswire/ -- Immorta Bio Inc., a pioneering longevity biotechnology company dedicated to Treating Diseases of Aging and Treating Aging as Disease™, today announced that acclaimed filmmaker and creative director
More news about: Immorta Bio Inc.
Feb 18, 2026, 08:23 ET BiomEdit Initiates Final Field Safety Trial for Non-Antibiotic Poultry Biologic, Advancing Toward USDA Conditional Licensure
GREENFIELD, Ind., Feb. 18, 2026 /PRNewswire/ -- BiomEdit, a pioneering animal health biotechnology company, today announced the initiation of the pivotal field safety trial for its lead candidate, BE-101, a non-antibiotic poultry biologic for
More news about: BiomEdit
Feb 18, 2026, 08:15 ET RoviSys Advances Regulated Industry Facilities Strategy, Names Chris Kulbago Director
discrete manufacturing automation solutions, is pleased to reaffirm its expanded facilities systems integration capabilities for pharmaceutical, biotechnology, and medical device manufacturers. As regulatory expectations increase and facilities become more complex, manufacturers require reliable and integrated
More news about: RoviSys
Feb 18, 2026, 08:00 ET Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products
BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture
More news about: Ginkgo Bioworks
Feb 18, 2026, 07:00 ET Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy Announce License Agreement for the Development of a Gene Therapy Using TfR1 CapX, an AAV Capsid Designed to Target the Central Nervous System
Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced a license agreement to support Finding Hope for
More news about: Apertura Gene Therapy
Feb 18, 2026, 06:59 ET Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that
More news about: Q32 Bio
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Feb 17, 2026, 16:05 ET Immunic Announces Closing of Oversubscribed Private Placement Financing
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its previously
More news about: Immunic, Inc.
Feb 17, 2026, 16:01 ET HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Feb 17, 2026, 11:42 ET Growth Factors Market to Reach US$ 3.7 Bn by 2033, Expands Amid Rising Regenerative Medicine and Biopharmaceutical Innovation - Persistence Market Research
manufacturing and R&D investment.Technological Innovation and Enhanced Biomanufacturing EfficiencyAdvancements in biotechnology are another significant driver of market growth. Improved methods for synthesizing high-activity growth factors and integration of quality-by-design
More news about: Persistence Market Research Pvt. Ltd.
Feb 17, 2026, 11:32 ET Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14,
More news about: Moonage Media
Feb 17, 2026, 11:23 ET AI in Biotechnology Market Size to Reach USD 1,971 Million by 2031 | Valuates Reports
https://reports.valuates.com/request/sample/QYRE-Auto-21X19811/Global_AI_in_Biotechnology_Market What are the key factors driving the growth of AI in the Biotechnology Market?● AI in biotechnology is being shaped by platform-driven
More news about: Valuates Reports